Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | DHPS | P49366 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792800 | 0.82 | AXL (0.32) | PRKCIAXLCCR4BRD4DHPS | |
| SCHEMBL24809910 | 0.74 | AXL (0.37) | PRKCIAXLAHRBRD4 | |
| SCHEMBL30501980 | 0.74 | AXL (0.44) | PRKCIAXLAHRBRD4 | |
| SCHEMBL22576128 | 0.74 | AXL (0.44) | PRKCIAXLAHRBRD4 | |
| SCHEMBL12395338 | 0.70 | TRPA1 (0.41) | PRKCIAXLAHRCCR4DHPS | |
| SCHEMBL2674872 | 0.70 | AHR (0.38) | PRKCIAXLAHRBRD4 | |
| SCHEMBL24809828 | 0.70 | TRPA1 (0.33) | PRKCIAXLCCR4BRD4 | |
| SCHEMBL22576507 | 0.70 | JAK1 (0.36) | — | |
| SCHEMBL22792993 | 0.68 | PDE3B (0.30) | — | |
| SCHEMBL13059117 | 0.68 | KIF11 (0.32) | PRKCIAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | PRKCI 308/4885AXL 1396/4885HPGD 2504/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | PRKCI 328/4885AXL 1050/4885HPGD 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.